Feedback / Questions
rademikibart (CBP-201) - Suzhou Connect Biopharma
Rademikibart: "Rademikibart Expected Utilization in Asthma and COPD"
(Connect Biopharma)
-
May 27, 2025 -
Corporate Presentation
Commercial
•
Asthma • Chronic Obstructive Pulmonary Disease • Immunology
https://investors.connectbiopharm.com/static-files/26515edd-b1bd-4f26-aef3-c56a5da2b5a9
May 27, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious